Guaifenesin

Evidence Level: L5

Predicted Indications: 4

Guaifenesin

Pharmacist Assessment Report

Guaifenesin: Nasal cavity disease

One-Sentence Summary

Guaifenesin is an expectorant that is mainly used for upper respiratory conditions such as rhinitis, pharyngitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, but the evidence is thin: no clinical trials and only 1 publication (a review) were found.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Nasal cavity disease
TxGNN Prediction Score	0.9998
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, guaifenesin is an expectorant that thins and loosens airway mucus. Its efficacy in rhinitis and related upper airway conditions is already recognised, and mechanistically it may be applicable to nasal cavity disease.

Nasal cavity disease is a broader category that includes the rhinitis conditions guaifenesin is already linked to. The plausible link is improved clearance of nasal and sinus secretions. This link is inferred and not confirmed.

The very high TxGNN score (0.9998) is a computational prediction. It probably reflects the overlap with existing rhinitis indications rather than independent evidence of a new benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
12487405	2002	Review	Logopedics, Phoniatrics, Vocology	Treatment strategies for hidden respiratory allergies in voice users; decongestants containing guaifenesin may be useful, while antihistamines are generally avoided

This is a single review focused on voice users. It offers only indirect support and does not test guaifenesin in nasal cavity disease.

India Market Information

Guaifenesin has 20 valid single-ingredient registrations in India and none are cancelled. The registration records do not include approved indication text. Five main authorizations are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
Registration No. 52663	Chestorex Tablet	Strip of 10 tablets	Not stated in the registration record
Registration No. 30353	Bro Surex Syrup	Bottle of 100 ml syrup	Not stated in the registration record
Registration No. 247511	Z Cof Syrup	Bottle of 100 ml syrup	Not stated in the registration record
Registration No. 176224	Prodexa Tablet	Strip of 10 tablets	Not stated in the registration record
Registration No. 26008	Broncorex Expectorant	Bottle of 100 ml syrup	Not stated in the registration record

Available forms include tablets, capsules and syrups.

Safety Considerations

Conditions flagged in the knowledge graph (not label text): The drug–disease contraindication links in the knowledge graph include hypertension, liver failure and liver disease, cirrhosis, kidney disease, epilepsy, COPD, peptic and gastric ulcer, inflammatory bowel disease, pancreatitis, porphyria, thrombocytopenia, adrenocortical insufficiency (Addison disease), hypothyroidism, anxiety and psychotic disorders, and insomnia. These links may partly reflect combination products and should be checked against the actual package insert.
Drug interactions: No interaction records were found.

Please refer to the package insert for confirmed warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high, but it likely reflects overlap with existing rhinitis indications. There are no clinical trials, only one indirect review, and the mechanism data are missing, so the evidence does not yet support a new indication.

To proceed, the following is needed:

Mechanism of action data for guaifenesin
Package insert warnings and contraindications for the India products, which are required before safety screening
Clinical studies of guaifenesin in nasal cavity disease, or a clear definition of how this differs from the existing rhinitis indications
Review of the knowledge-graph contraindication signals against the label

Other Predicted Indications (Not Recommended for Now)

All have no trials or literature and are rated L5 (model prediction only):

Predicted Indication	TxGNN Score	Comment
Faucial diphtheria	0.9954	Treatment relies on antitoxin and antibiotics; guaifenesin has no such activity (Hold)
Cervical disc degenerative disorder	0.9950	No clear mechanistic link (Hold)
Papillary conjunctivitis	0.9927	Tenuous link through allergy only; no ocular mechanism (Hold)

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.